Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

EB103

Cell therapy · Kills target cells, directed at CD19 · developed by Estrella Immunopharma

Phase 1/2 Most advanced trial

ESLA Developer

1 Registered trials

What is EB103?

EB103 is an autologous T-cell therapy in which a patient's T cells are transduced with a lentiviral vector expressing an antibody-T-cell-receptor (AbTCR) targeting CD19 and a co-stimulatory molecule. The engineered T cells recognize and kill CD19-expressing B-cell lymphomas, including relapsed and refractory non-Hodgkin lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy
Targets: CD19 (antigen)
Mechanism: Kills target cells, directed at CD19
Pathways: T-cell-mediated cytotoxicity
Therapy area: Oncology
Developer: Estrella Immunopharma, Inc. (ESLA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06343311	Phase 1/2	B-Cell Non-Hodgkin's Lymphoma (NHL)	Recruiting	ESLA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

B-Cell Non-Hodgkin's Lymphoma (NHL)CNS LymphomaHigh-grade B-cell LymphomaHIV Associated LymphomaLarge B-Cell LymphomaLymphomaLymphoma, Non-HodgkinLymphoma, Non-Hodgkin's, AdultLymphomas Non-Hodgkin's B-CellNon-Hodgkin LymphomaNon-Hodgkin's LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaRelapsed Non-Hodgkin Lymphoma

Other drugs acting on CD19

Blinatumomab FDA approved Inebilizumab FDA approved Loncastuximab tesirine FDA approved Budoprutug Phase 1/2 MK-1045 Phase 2/3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ESLA page.

Follow ESLA, the company behind EB103

See ESLA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ESLA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z